Welcome to Medical News Today

Healthline Media, Inc. would like to process and share personal data (e.g., mobile ad id) and data about your use of our site (e.g., content interests) with our third party partners (see a current list) using cookies and similar automatic collection tools in order to a) personalize content and/or offers on our site or other sites, b) communicate with you upon request, and/or c) for additional reasons upon notice and, when applicable, with your consent.

Healthline Media, Inc. is based in and operates this site from the United States. Any data you provide will be primarily stored and processed in the United States, pursuant to the laws of the United States, which may provide lesser privacy protections than European Economic Area countries.

By clicking “accept” below, you acknowledge and grant your consent for these activities unless and until you withdraw your consent using our rights request form. Learn more in our Privacy Policy.

Please accept our privacy terms

We use cookies and similar technologies to improve your browsing experience, personalize content and offers, show targeted ads, analyze traffic, and better understand you. We may share your information with third-party partners for marketing purposes. To learn more and make choices about data use, visit our Advertising Policy and Privacy Policy. By clicking “Accept and Continue” below, (1) you consent to these activities unless and until you withdraw your consent using our rights request form, and (2) you consent to allow your data to be transferred, processed, and stored in the United States.

Register for a free account

Stress urinary incontinence drug's benefits do not outweigh harms

Published
Tuesday 15 November 2016 Published Tue 15 Nov 2016

Adapted Media Release

A new study indicates that the benefits of duloxetine, a drug used in Europe to treat stress incontinence in women, do not outweigh the harms. The article is published in CMAJ (Canadian Medical Association Journal).

Duloxetine, a drug approved in Canada, the US and Europe to treat major depression, is approved in Europe to treat stress urinary incontinence - involuntary leakage of urine during exertion, sneezing or coughing - that affects an estimated 1 in 10 women.

The US Food and Drug Administration has noted a higher-than-expected rate of suicide attempts in open-label extensions of controlled trials of duloxetine for stress urinary incontinence.

Researchers from the Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark, looked at clinical study reports from the European Medicines Agency to assess the benefits and harms of using this drug for stress urinary incontinence. Although they found that duloxetine did lessen the frequency of incontinence, they also observed adverse effects associated with the drug. Harms potentially related to suicidality and violence were 4 to 5 times more common with duloxetine than with a placebo.

"Given the uncertainty as to whether duloxetine leads to clinically significant improvement in quality of life ... we question the rationale for using duloxetine for stress urinary incontinence," writes Emma Maund, lead author and researcher at the Nordic Cochrane Centre, with coauthors.

2018 Healthline Media UK Ltd. All rights reserved. MNT is the registered trade mark of Healthline Media. Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional.